peptide
Liraglutide
strongFDA-Approved· RxInjection
First-gen GLP-1 drug (Saxenda/Victoza). Less potent than semaglutide but has years of clinical data and established safety profile. Requires daily injection.
Key facts
- Classification
- Peptide — First-gen GLP-1 drug (Saxenda/Victoza). Effective but weaker than semaglutide.
- Primary benefits
- Fat Loss (8/10) · Longevity (4/10) · Gut Health (3/10)
- Administration
- Injection
- Doses studied
- Start at 0.6 mg per day and gradually increase to 3.0 mg per day over several weeks. Daily injection required (shorter-lasting than semaglutide).
- Evidence strength
- Strong — 20 peer-reviewed studies
- Stacks well with
- 5-Amino-1MQ, BPC-157, MOTS-c
- Legal status
- FDA-Approved · prescription required · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 3 peptides
- Regulatory
- FDA-Approved
Goal coverage · Liraglutide
🔥 Fat Loss8/10
⏳ Longevity4/10
🫃 Gut Health3/10
🧊 Inflammation2/10
Medical oversight requiredNot safe during pregnancy· 4 contraindications